SCLC, EXTENSIVE STAGE
Clinical trials for SCLC, EXTENSIVE STAGE explained in plain language.
Never miss a new study
Get alerted when new SCLC, EXTENSIVE STAGE trials appear
Sign up with your email to follow new studies for SCLC, EXTENSIVE STAGE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test 'Off-the-Shelf' supercharged immune cells against aggressive lung cancer
Disease control Recruiting nowThis early-stage trial is testing whether specially engineered immune cells can fight advanced small cell lung cancer that has stopped responding to standard treatments. Researchers will give patients immune cells from healthy donors that have been modified to recognize and attac…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Apr 01, 2026 22:56 UTC
-
New combo therapy aims to keep aggressive lung cancer at bay
Disease control Recruiting nowThis study is testing whether adding an oral chemotherapy pill (etoposide capsules) to an immunotherapy drug (adebrelimab) can help control extensive-stage small cell lung cancer after initial treatment. The trial will involve 32 patients in China whose cancer hasn't gotten worse…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug combo tested to keep aggressive lung cancer at bay
Disease control Recruiting nowThis study is testing whether adding a new drug called golidocitinib to standard immunotherapy (PD-1 inhibitors) can help control extensive-stage small cell lung cancer for longer. After initial chemotherapy, participants receive the two-drug combination as maintenance therapy to…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for Tough-to-Treat lung cancer: drug combo trial seeks to extend remission
Disease control Recruiting nowThis trial is testing whether adding a drug called niraparib to standard immunotherapy maintenance can help control advanced small cell lung cancer for longer. It is for patients whose cancer has a specific biomarker (SLFN11-positive) and has not worsened after initial chemothera…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Targeted radiation & immune therapy tested for tough lung cancer
Disease control Recruiting nowThis early-stage study is testing the safety and initial effectiveness of a new combination treatment for advanced small cell lung cancer. It combines a radioactive drug that targets specific tumor markers with an immunotherapy drug, given as a maintenance therapy after initial c…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE1 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New drug combo tested for Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug called HLX10 to standard chemotherapy helps control advanced small cell lung cancer. It is for Japanese patients who have not yet received any treatment for their extensive-stage cancer. The main goal is to see how wel…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New pill offers hope for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing an experimental daily pill called ABP1011T for people with advanced solid tumors, like certain lung, esophageal, and cervical cancers, who have already tried and stopped responding to standard treatments. The main goal is to see if the pill can shrink tumors…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Shanghai AB PharmaTech Ltd. • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC
-
Engineered virus fights back against tough lung cancer
Disease control Recruiting nowThis study is testing whether adding a modified virus called Olvi-Vec to standard chemotherapy can help control advanced small cell lung cancer that has returned or stopped responding to previous platinum-based treatments. The research aims to see if this combination is safe and …
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE1, PHASE2 • Sponsor: Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Feb 23, 2026 14:51 UTC